Personalized medicine in diabetic kidney disease: a novel approach to improve trial design and patient outcomes

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)

Abstract

Purpose of review

In the last decade many attempts have been made to reduce the high residual risk of end-stage kidney disease and cardiovascular disease in patients with diabetic kidney disease by targeting a variety of risk markers. Subsequent analyses revealed that the variation in individual drug response to the tested interventions partly explains why these trials did not result in additional kidney or cardiovascular protection. This review summarizes recent insights regarding individual variation in drug response. Additionally, we explore novel approaches to incorporate this drug response variability in the design of new clinical trials.

Recent findings

Recent studies suggest that a plausible explanation for individual therapy resistance emanates from intrinsic individual characteristics such as genetic make-up or volume status and is likely only partially explained by drug characteristics such as the dose or type of intervention. Biomarker-based enrichment strategies to identify high-risk individuals and/or those who are more likely to respond to interventions offer opportunities to tailor therapies to individual patients.

Summary

Individual drug response variability is a recognized phenomenon in clinical practice. It is time to implement novel approaches that take into account this response variability in the design of new trials in diabetic kidney disease in order to define optimal therapies for individual patients.

Original languageEnglish
Pages (from-to)426-432
Number of pages7
JournalCURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
Volume27
Issue number6
Early online date7-Aug-2018
DOIs
Publication statusPublished - Nov-2018

Keywords

  • cardiovascular outcomes
  • diabetic kidney disease
  • drug response variability
  • enrichment
  • risk markers
  • POST-HOC ANALYSIS
  • RISK-FACTORS
  • URINARY-EXCRETION
  • HEART-FAILURE
  • END-POINTS
  • TYPE-2
  • RECEPTOR
  • PROTEINURIA
  • LOSARTAN
  • RENOPROTECTION

Cite this